Key terms

About MCK

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest MCK news

Today 2:09am ET McKesson: Hold Rating Amidst Strong Outlook and Valuation Concerns Yesterday 9:02am ET McKesson price target lowered to $545 from $547 at Deutsche Bank Yesterday 6:31am ET McKesson price target raised to $551 from $502 at Wells Fargo May 08 8:43am ET McKesson price target raised to $600 from $590 at Evercore ISI May 08 8:40am ET McKesson price target raised to $617 from $606 at Leerink May 08 7:32am ET McKesson price target raised to $596 from $571 at Barclays May 08 7:29am ET McKesson price target raised to $590 from $566 at BofA May 08 7:25am ET McKesson price target raised to $652 from $563 at TD Cowen May 07 9:01pm ET Analysts Offer Insights on Healthcare Companies: McKesson (MCK) and Perrigo Company (PRGO) May 07 4:16pm ET McKesson sees FY25 adjusted EPS $31.25-$32.50, consensus $31.02 May 07 4:15pm ET McKesson reports Q4 adjusted EPS $6.18, consensus $6.34 Apr 30 5:45pm ET Cardinal Health Stock (NYSE:CAH): Dip Creates Long-Term Opportunity Apr 29 9:33pm ET McKesson price target raised to $620 from $575 at Citi Apr 24 9:02am ET Cardinal Health price target lowered to $110 from $118 at Evercore ISI Apr 24 4:46am ET Barclays Reaffirms Their Buy Rating on McKesson (MCK) Apr 24 2:26am ET Buy Rating Reaffirmed for McKesson Amid Strong Growth Prospects and OptumRx Contract Win Apr 22 12:15pm ET Buy Rating Affirmed: McKesson’s Strategic Growth Bolstered by OptumRx Contract Win Apr 22 9:25am ET McKesson won OptumRx contract lost by Cardinal, says Evercore Apr 16 12:20am ET Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), McKesson (MCK) Mar 25 8:25pm ET Notable companies reporting before tomorrow’s open Mar 25 1:47pm ET Notable companies reporting before tomorrow’s open Mar 17 6:44am ET McCormick stock about to shake things up, Barron’s says Mar 12 7:16am ET Rockwell Automation announces Stephen Ford as chief information security officer Mar 06 7:59am ET McKesson price target raised to $620 from $575 at UBS Feb 26 7:20am ET Analysts Are Bullish on Top Healthcare Stocks: BeiGene (BGNE), McKesson (MCK) Feb 26 6:21am ET McKesson initiated with an Outperform at Leerink Feb 14 5:12pm ET Third Point buys McKesson, exits T-Mobile in Q4 Feb 14 10:01am ET FTC probing drug distributors over low supplies of chemotherapies, WSJ reports Feb 12 5:50am ET Analysts Offer Insights on Healthcare Companies: McKesson (MCK), Embecta Corporation (EMBC) and Abbott Labs (ABT)

No recent press releases are available for MCK

MCK Financials

1-year income & revenue

Key terms

MCK Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

MCK Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms